

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

January 21, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held on even date, i.e. January 21, 2025, have approved the following capital expenditure(s):

- A. Enhancement of capacity at our Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The requisite details are as under:

a) Existing Capacity	0.5 KL - (Peptide Synthesizers)
b) Existing Capacity Utilization	30%
c) Proposed Capacity Addition	6.37 KL - (Peptide Synthesizers)
d) Period within which the proposed capacity is to be added	FY'27
e) Investment required	₹ 254 crores (Inclusive of GST)
f) Mode of financing	Through borrowings and Internal accruals
g) Rationale	Development and commercial production of Peptides for GDS & CMS business

- B. Enhancement of capacity at our Unit 3 located Gaddapotharam Village, Jinnaram Mandal, Sangareddy District, Telangana. The requisite details are as under:

a) Existing Capacity (Unit 3)	321 KL
b) Existing Capacity Utilization (Unit 3)	40%
c) Proposed Capacity Addition	52 KL
d) Period within which the proposed capacity is to be added	15 to 18 months
e) Investment required	₹ 88 crores (Inclusive of GST)
f) Mode of financing	Through internal accruals
g) Rationale	To maintain and cater to the growing demand of our customers.

A note on the above approved capital expenditure(s) is enclosed as **Annexure**.

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Neuland Labs Board approves Capital Expenditure of Rs 342 crores

Neuland Laboratories Limited (“**Neuland Labs**”) has invested in the niche technology area of Peptides over the last 15 years and has made progress at the Laboratory scale on various projects in the CMS & GDS businesses. Considering the business opportunities and to capitalize on current capabilities, the Company is planning to build a new Peptide block with significant peptide manufacturing capacity at its Unit-1, allowing the business to scale. The Board’s approval of this investment of Rs 254 Cr will enhance the Company’s Peptide Synthesizer reactor capacity from 0.5 KL to 6.37 KL. The Company plans to fund this CAPEX through debt and internal accruals. The Company expects the project to be completed by FY27. This peptide manufacturing block will be a multi-product facility servicing the needs of both CMS and GDS customers.

The Board has also approved an investment of Rs. 88 Cr towards building an additional capacity of 52 KL in its Unit-3. This capacity is expected to come online in 15 to 18 months.

These investments are in line with the Company’s long-term growth strategy as articulated in past communications.